14/03/2019 - 09:01

Early success for PharmAust’s cancer drug trial

14/03/2019 - 09:01


Save articles for future reference.

PharmAust is basking in the early success of Phase I clinical trials for its flagship anti-cancer drug Monepantel in dogs. Preliminary results show that the blood concentrations of Monepantel in the test subjects already exceeded levels observed to achieve anti-cancer activity after administrating just one tablet. The company has now started the dose escalation component of the Phase I trial on schedule.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options